A detailed history of Smith Thornton Advisors LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Smith Thornton Advisors LLC holds 2,691 shares of GILD stock, worth $251,339. This represents 0.15% of its overall portfolio holdings.

Number of Shares
2,691
Holding current value
$251,339
% of portfolio
0.15%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

BUY
$66.59 - $83.99 $179,193 - $226,017
2,691 New
2,691 $226 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $117B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Smith Thornton Advisors LLC Portfolio

Follow Smith Thornton Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Smith Thornton Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Smith Thornton Advisors LLC with notifications on news.